Evidence map›Paper›PMID 40075639›Full record

ArticleCancers2025

Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis.

Bianca Romo, Zenaida Fuentes, Lois Randolph, Megharani Mahajan, Emily J Aller, Behnam Ebrahimi, Bindu Santhamma, Uday P Pratap, Panneerdoss Subbarayalu, Harika Nagandla and 4 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bianca RomoDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Zenaida FuentesDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0009-0009-7676-4449
Lois RandolphDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Megharani MahajanDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Emily J AllerDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Behnam EbrahimiDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Bindu SanthammaEvestra, Inc., San Antonio, TX 78245, USA.
Uday P PratapDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Panneerdoss SubbarayaluMays Cancer Canter, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Harika NagandlaHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Christoforos ThomasHouston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA.ORCID 0000-0003-3003-2954
Hareesh B NairDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Ratna K VadlamudiDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0003-2849-4076
Suryavathi ViswanadhapalliDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-7381-6962

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Novel targeted therapy for treating Ovarian CancerR01CA266970 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Bindu Santhamma, Ratna K Vadlamudi · 2022 to 2026
$3.3M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM145432 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jose E Cavazos, Ratna K Vadlamudi · 2023 to 2026
$2.3M
Development of new therapeutic approaches for endometrial cancerR01CA267893 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI VADLAMUDI, RATNA K, VISWANADHAPALLI, SURYAVATHI · 2022 to 2025
$1.7M
UTHealth-LINK- A PREP programR25GM130437 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HOPP, SARAH CHRISTINE, OYAJOBI, BABATUNDE OLUKAYODE · 2020 to 2024
$1.6M
Targeting the RNA modifying enzyme ALKBH5 in MedulloblastomaR21CA277164 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SUBBARAYALU, PANNEERDOSS · 2023 to 2024
$353k
BLRD VA I01 BX006280NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA266970NCI NIH HHS R01 CA267893NCI NIH HHS R21 CA277164NIGMS NIH HHS R25 GM130437NIGMS NIH HHS T32 GM145432NIH HHS 1R01CA266970-24A1NIH HHS 1R01CA267893-24A1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

EC359IBCLIFLIFR

Identifiers

PMID40075639
PMCPMC11898489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.